Vertex Pharmaceuticals Inc / Ma (VRTX) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Vertex Pharmaceuticals Inc / Ma reported revenue of $12.00B, up 8.9% from $11.02B the year before. Net income was $3.95B (a 32.9% net margin), or $15.32 per diluted share. Gross margin was 86.2% and operating margin was 34.8%. Operating activities generated $3.63B of cash, leaving $3.19B of free cash flow. At fiscal year end, Vertex Pharmaceuticals Inc / Ma held $25.64B in total assets against $6.98B in total liabilities, including $5.08B of cash and equivalents.
Open the full interactive Vertex Pharmaceuticals Inc / Ma financials → Quarterly statements, key ratios, valuation history and price charts.
Vertex Pharmaceuticals Inc / Ma Key Stats
| Share Price | $485.22 |
|---|---|
| Market Cap | $123.83B |
| P/E Ratio | 31.7 |
| Revenue YoY Growth | +8.9% |
| 52-Week Range | $407.37 – $557.96 |
| Shares Outstanding | 253.7 million (basic, 2026 Q2) |
Vertex Pharmaceuticals Inc / Ma Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $6.21B | $7.57B | $8.93B | $9.87B | $11.02B | $12.00B |
| Cost of Goods Sold | $736.3M | $904.2M | $1.08B | $1.26B | $1.53B | $1.65B |
| Gross Profit | $5.47B | $6.67B | $7.85B | $8.61B | $9.49B | $10.35B |
| Operating Income | $2.86B | $2.78B | $4.31B | $3.83B | -$232.9M | $4.17B |
| Pre-Tax Income | $3.12B | $2.73B | $4.23B | $4.38B | $248.5M | $4.64B |
| Income Tax | $405.2M | $388.3M | $910.4M | $760.2M | $784.1M | $690.0M |
| Net Income | $2.71B | $2.34B | $3.32B | $3.62B | -$535.6M | $3.95B |
| Diluted EPS | $10.29 | $9.01 | $12.82 | $13.89 | -$2.08 | $15.32 |
Vertex Pharmaceuticals Inc / Ma Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $3.08B | $3.19B | $2.99B | $3.33B |
| Net Income | $1.08B | $1.19B | $1.03B | $1.10B |
| Diluted EPS | $4.20 | $4.62 | $4.02 | $4.31 |
Vertex Pharmaceuticals Inc / Ma Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.99B | $6.79B | $10.50B | $10.37B | $4.57B | $5.08B |
| Current Assets | $8.13B | $9.56B | $13.23B | $14.14B | $9.60B | $11.20B |
| Total Assets | $11.75B | $13.43B | $18.15B | $22.73B | $22.53B | $25.64B |
| Current Liabilities | $1.88B | $2.14B | $2.74B | $3.55B | $3.56B | $3.86B |
| Total Liabilities | $3.06B | $3.33B | $4.24B | $5.15B | $6.12B | $6.98B |
| Shareholders' Equity | $8.69B | $10.10B | $13.91B | $17.58B | $16.41B | $18.67B |
Vertex Pharmaceuticals Inc / Ma Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $3.25B | $2.64B | $4.13B | $3.54B | -$492.6M | $3.63B |
| Cash From Investing | $99.4M | -$340.9M | -$321.1M | -$3.14B | -$3.77B | -$945.4M |
| Cash From Financing | -$505.3M | -$1.48B | -$67.7M | -$562.2M | -$1.49B | -$2.26B |
| Free Cash Flow | $2.99B | $2.41B | $3.93B | $3.34B | -$790.3M | $3.19B |
Figures from Vertex Pharmaceuticals Inc / Ma's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Vertex Pharmaceuticals Inc / Ma financials page for every line item.
Vertex Pharmaceuticals Inc / Ma Company Profile
| Ticker | VRTX |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Boston, Massachusetts |
| Incorporated in | Massachusetts |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0000875320 |
Frequently Asked Questions
What was Vertex Pharmaceuticals Inc / Ma's revenue in fiscal 2025?
Vertex Pharmaceuticals Inc / Ma (VRTX) reported revenue of $12.00B for fiscal 2025.
What is Vertex Pharmaceuticals Inc / Ma's annual revenue history?
Vertex Pharmaceuticals Inc / Ma's annual revenue by fiscal year: 2020: $6.21B; 2021: $7.57B; 2022: $8.93B; 2023: $9.87B; 2024: $11.02B; 2025: $12.00B.
What was Vertex Pharmaceuticals Inc / Ma's net income in fiscal 2025?
Vertex Pharmaceuticals Inc / Ma reported net income of $3.95B for fiscal 2025.
What was Vertex Pharmaceuticals Inc / Ma's earnings per share (EPS) in fiscal 2025?
Vertex Pharmaceuticals Inc / Ma's diluted EPS was $15.32 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Vertex Pharmaceuticals Inc / Ma generate in fiscal 2025?
Vertex Pharmaceuticals Inc / Ma generated $3.19B of free cash flow in fiscal 2025.
What was Vertex Pharmaceuticals Inc / Ma's revenue last quarter?
In its most recent reported quarter (2026 Q2), Vertex Pharmaceuticals Inc / Ma reported revenue of $3.33B.
How many shares of Vertex Pharmaceuticals Inc / Ma are outstanding?
Vertex Pharmaceuticals Inc / Ma reported a weighted average of 253.7 million basic shares outstanding in 2026 Q2.
What is Vertex Pharmaceuticals Inc / Ma's market cap?
Based on its latest closing price, Vertex Pharmaceuticals Inc / Ma (VRTX) has a market capitalization of about $123.83B.
When does Vertex Pharmaceuticals Inc / Ma's fiscal year end?
Vertex Pharmaceuticals Inc / Ma's fiscal year end, as registered with the SEC, is December 31.
Where is Vertex Pharmaceuticals Inc / Ma headquartered?
Vertex Pharmaceuticals Inc / Ma lists its business address in Boston, Massachusetts in its SEC filings.